Tumor response evaluation in oncology: current update.
Quantification of tumor burden and assessment of changes in tumor size after chemotherapy are commonly performed to evaluate treatment response in oncology trials. Validation and adoption of different criteria have been attempted in the past to achieve uniformity in scanning techniques and measurement metrics so that comparison of different oncological trials is feasible. Response assessment of solid tumors is usually consisted of either bidimensional (World Health Organization criteria) or unidimensional (Response Evaluation Criteria in Solid Tumors [RECIST] guidelines) measurement of tumors before and after chemotherapy. RECIST 1.1 criteria have been recently published. In this article, we try to provide a comprehensive review of the tumor response evaluation guidelines that were recently updated in attempts to overcome limitations of the previous criteria as well as incorporate recent advances in imaging techniques.
Shanbhogue
Alampady Krishna Prasad
AK
Department of Radiology, University of Texas HSC at San Antonio, San Antonio, TX 78229, USA. shanbhogue@uthscsa.edu
Karnad
Anand B
AB
Prasad
Srinivasa R
SR
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017408:Guidelines as Topic; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008495:Medical Oncology / Q000379:methods* / Q000639:trends; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000639:trends; D049268:Positron-Emission Tomography / Q000379:methods; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods; D014057:Tomography, X-Ray Computed / Q000379:methods; D047368:Tumor Burden / Q000187:drug effects*; D014944:World Health Organization
D000970:Antineoplastic Agents